Di Molfetta, S.
Patruno, P.
Cormio, S.
Cignarelli, A.
Paleari, R.
Mosca, A.
Lamacchia, O.
De Cosmo, S.
Massa, M.
Natalicchio, A.
Perrini, S.
Laviola, L.
Giorgino, F. http://orcid.org/0000-0001-7372-2678
Clinical trials referenced in this document:
Documents that mention this clinical trial
A telemedicine-based approach with real-time transmission of blood glucose data improves metabolic control in insulin-treated diabetes: the DIAMONDS randomized clinical trial
https://doi.org/10.1007/s40618-022-01802-w
Funding for this research was provided by:
Eli Lilly and Company
LifeScan
Article History
Received: 16 January 2022
Accepted: 5 April 2022
First Online: 27 April 2022
Declarations
:
: AC: Eli Lilly, Novo Nordisk, Sanofi Aventis, AstraZeneca, Bruno farmaceutici, Roche, Alfa Sigma. AN: AstraZeneca, Novo Nordisk, Sanofi Aventis. FG: Abbott, Medtronic, Roche Diabetes Care Italy, Lifescan. LL: Abbott, Medtronic, Movi, Roche Diabetes Care Italy. OL: AstraZeneca, Eli Lilly, Novo Nordisk. SDM: Abbott, Roche Diabetes Care Italy. SP declares to be a member of the Editorial Board of the Journal of Endocrinological Investigation. AM, MM, PP, RP, SC, and SDC declare that they have no conflict of interest.
: The study was carried out in adherence to Good Clinical Practice, ICH Harmonized Tripartite Guidelines for Good Clinical Practice and Declaration of Helsinki.
: All participants provided informed consent for participation in the study.